1. The First Wave of Medicare Drug Price Negotiations

In 2025, the Centers for Medicare & Medicaid Services (CMS) finalized its first-ever list of drugs selected for Medicare price negotiations.

The negotiated prices will officially take effect on January 1, 2026, benefiting millions of older adults across the country.

These drugs were chosen because they:

Account for the highest total Medicare spending

Have no generic or biosimilar competition

Have been on the market for more than nine years (small-molecule drugs) or 13 years (biologics)

💡 Key goal: Reduce out-of-pocket costs for patients who depend on high-cost brand-name drugs.

2. Top Medications with Price Reductions in 2026

The first round of negotiations includes 10 high-spending drugs that treat common conditions such as diabetes, heart disease, and cancer.

Drugs selected for 2026 price reductions:

Eliquis (apixaban) – prevents blood clots and stroke

Jardiance (empagliflozin) – manages type 2 diabetes and heart failure

Xarelto (rivaroxaban) – anticoagulant used for clot prevention

Farxiga (dapagliflozin) – diabetes and chronic kidney disease treatment

Januvia (sitagliptin) – type 2 diabetes medication

Entresto (sacubitril/valsartan) – heart failure medication

Imbruvica (ibrutinib) – blood cancer treatment

Enbrel (etanercept) – autoimmune conditions such as arthritis and psoriasis

Fiasp/NovoLog (insulin aspart) – rapid-acting insulin

Stelara (ustekinumab) – psoriasis and Crohn’s disease treatment

💡 Estimated savings: Between 30% and 60% off current prices, depending on the medication.

3. How Much Will Patients Save?

The price cuts are expected to save Medicare beneficiaries hundreds to thousands of dollars annually, depending on their prescriptions.

Examples of potential annual savings (per patient):

Eliquis: Up to $800 per year

Jardiance: Around $500–$700 per year

Xarelto: Roughly $600–$900 per year

Entresto: Up to $1,000 per year

💡 Note: These savings apply directly to Medicare Part D beneficiaries and will automatically appear in their 2026 pharmacy pricing — no extra steps required.

4. How the Inflation Reduction Act Made This Possible

The Inflation Reduction Act (IRA), signed in 2022, granted Medicare the authority to negotiate directly with pharmaceutical companies — something that was previously prohibited.

Key provisions include:

Medicare Drug Price Negotiation Program: Enables direct price talks for high-cost medications.

$2,000 Out-of-Pocket Cap (2025): Medicare Part D enrollees will not pay more than $2,000 annually for covered prescriptions.

Inflation Rebates: Drugmakers must reimburse Medicare if they raise prices faster than inflation.

Expanded Low-Income Subsidy Program: More seniors now qualify for full cost-sharing assistance.

💡 Impact: Combined, these measures are projected to save the federal government $98 billion over the next decade — while lowering costs for millions of patients.

5. Who Benefits Most

The 2026 price reductions will primarily benefit:

Medicare Part D beneficiaries with chronic conditions like diabetes, heart failure, or arthritis.

Fixed-income seniors who previously skipped doses or rationed medication due to cost.

Healthcare systems that rely on Medicare reimbursements for drug coverage.

💡 By 2028, an estimated 40% of all Medicare drug spending will fall under negotiated pricing.

6. Will Private Insurance Plans See Similar Cuts?

While the new pricing applies only to Medicare, commercial insurance plans and employer-based coverage are expected to follow suit.

Pharmaceutical companies often lower their wholesale prices once Medicare’s negotiated rates are public to maintain market consistency.

💡 Tip: If you’re under 65 and not on Medicare, monitor your insurer’s 2026 formulary — many private plans will adjust copays and preferred drug lists accordingly.

7. What’s Next: The 2027 and 2028 Expansion

The drug negotiation program will expand over the next few years:

2027: 15 additional Medicare Part D drugs will receive negotiated prices.

2028: 15 more, including Part B (physician-administered) medications.

2029 and beyond: 20 new drugs added annually.

This gradual rollout ensures long-term, sustainable reductions without disrupting pharmaceutical innovation or access.

8. What Patients Should Do Now

Review your current medications and note which are on the 2026 list.

Talk to your doctor or pharmacist about how price changes could affect your plan.

Check your 2026 Medicare Part D plan during Open Enrollment (Oct 15 – Dec 7, 2025).

Stay updated via Medicare.gov — official price reductions will be published in late 2025.

💡 Pro Tip: Many pharmacies and insurers will start updating their price lookup tools as early as fall 2025.